Our guest today is Mati Gill, CEO of AION Labs. AION Labs has an innovative company creation process that empowers startups to tackle high-impact challenges with AI, backed by top-tier data, funding, and expertise.
The post AION Labs is building innovative biotechs with top pharma partners in Israel appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M
With positive Phase 1 results for the metabolic disorder drug MZE782, Maze Therapeutics plans to advance the small molecule to Phase 2 tests in phenylketonuria
